Adaptive Biotechnologies (ADPT) Depreciation and Depletion (2018 - 2026)

Adaptive Biotechnologies has disclosed Depreciation and Depletion across 9 years of filings, most recently posting $3.4 million for Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $3.4 million, down 20.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.2 million (down 10.94% YoY), and the FY2025 annual result was $16.1 million, down 8.28% from the prior year.
• Depreciation and Depletion came in at $3.4 million for Q1 2026 at Adaptive Biotechnologies, down from $3.7 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $5.3 million in Q3 2023 to a low of $3.4 million in Q1 2026.
• The 5-year median for Depreciation and Depletion is $4.6 million (2022), against an average of $4.5 million.
• Across the five-year window, Depreciation and Depletion soared 105.91% in 2022 and fell 21.97% in 2024, its largest moves.
• Adaptive Biotechnologies' Depreciation and Depletion stood at $4.9 million in 2022, then advanced by 2.18% to $5.0 million in 2023, then retreated by 19.0% to $4.0 million in 2024, then slipped by 7.16% to $3.7 million in 2025, then retreated by 8.41% to $3.4 million in 2026.
• The last three Depreciation and Depletion figures came in at $3.4 million (Q1 2026), $3.7 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.